

CSRC NOAC Think Tank: Commercial Payer Perspectives

February 3, 2015

Brian Caveney, MD, JD, MPH

Vice President & Medical Director





+ Patient Safety

- Clear & quantitative definition of “severe bleeding”
- Time elapsed from last dose & biomarkers to follow
- What SAE’s are possible if wrong reversal agent given?

+ Continuum of Clinical Efficacy

- Clinical decision support or data registry of use
- PGx, NOAC, serial measures, matched reversal, restart
- Create a global event score (thrombotic & bleeding events)

+ Coverage & Reimbursement

- “Covered” versus paid
- Price sensitivity, OOP maximums
- Medically necessary – not convenience of patient, caretaker, provider
- Value-based reimbursement contracts & bundles
- Elective procedures, never events
- Total cost of care: time, waiting, dialysis, reversal